CEDRA: A Tool to Help Consumers Assess Risk for Ear Disease.

This is a perspectives paper reporting an initial validation, not a completed larger validation; a larger more representative study is still ongoing. The validation sample was not a random representative sample of the United States, and it was chosen to have many people with targeted ear disease: 75% had one or more targeted ear disease. The sample was also unusual in race, ethnicity and education, with 91% White, 73% White not-Hispanic or Latino, and 52.4% having an undergraduate degree or graduate study, so real-world usability may be lower. CEDRA was tested only for 104 targeted ear diseases, not for other problems that can affect hearing aid use, such as earwax impaction. The initial validation considered only whether a targeted ear disease was present, not how severe it was. Formal usability testing beyond cognitive interviews has not been done, and older adults have lower health literacy than younger adults. The paper's 5% prevalence example gives 33 suggested evaluations, 4 targeted ear diseases, and 29 false alarms with training-sample characteristics, and 23 suggested evaluations, 4 targeted ear diseases, and 19 false alarms with test-sample characteristics.

No author conflicts or funding declaration are stated in the supplied text. The publication types indicate NIH extramural and non-U.S. government research support.

Do not read a low CEDRA score as proof that someone has no ear disease or is a suitable hearing aid candidate. The tool only screens for risk; it does not diagnose disease or assess severity.